CONTEXT: Visceral adiposity is associated with increased cardiometabolic risk and decreased GH secretion. OBJECTIVE: Our objective was to determine the effects of GH administration in abdominally obese young men on body composition, including liver fat, mitochondrial function, and cardiovascular (CV) risk markers. DESIGN AND PARTICIPANTS: This was a 6-month, randomized, double-blind, placebo-controlled study with 62 abdominally obese men (IGF-1 below the mean, no exclusion based on GH level), 21 to 45 years of age. MAIN OUTCOME MEASURES: We evaluated abdominal fat depots, thigh muscle and fat (computed tomography), fat and lean mass (dual-energy x-ray absorptiometry), intramyocellular and intrahepatic lipids (proton magnetic resonance spectroscopy), mitochondrial function (dynamic phosphorous magnetic resonance spectroscopy), CV risk markers, carotid intimal-medial thickness, and endothelial function. RESULTS:GH administration resulted in a mean IGF-1 SD score increase from -1.9 ± 0.08 to -0.2 ± 0.3 in the GH group and a decrease in visceral adipose tissue (VAT), VAT/sc adipose tissue, trunk/extremity fat, intrahepatic lipids, high-sensitivity C-reactive protein and apolipoprotein B/low-density lipoprotein vs placebo after controlling for the increase in weight observed in both groups. There were inverse associations between change in IGF-1 levels and change in VAT, VAT/sc adipose tissue, trunk fat, trunk/extremity fat, high-sensitivity C-reactive protein, and apolipoprotein B. Mitochondrial function improved in the GH group compared with placebo after controlling for change in glucose. There was no change in thigh fat, muscle mass, intramyocellular lipids, cholesterol, fibrinogen, intimal-medial thickness, or endothelial function. There was no increase in fasting glucose or hemoglobin A1c in the GH vs placebo group, although glucose during the 2-hour oral glucose tolerance test increased slightly. CONCLUSION:GH replacement in abdominally obese men improves body composition, including liver fat, mitochondrial function, and markers of CV risk. Although fasting glucose was unchanged, a slight increase in 2-hour glucose during an oral glucose tolerance test was noted.
RCT Entities:
CONTEXT: Visceral adiposity is associated with increased cardiometabolic risk and decreased GH secretion. OBJECTIVE: Our objective was to determine the effects of GH administration in abdominally obese young men on body composition, including liver fat, mitochondrial function, and cardiovascular (CV) risk markers. DESIGN AND PARTICIPANTS: This was a 6-month, randomized, double-blind, placebo-controlled study with 62 abdominally obesemen (IGF-1 below the mean, no exclusion based on GH level), 21 to 45 years of age. MAIN OUTCOME MEASURES: We evaluated abdominal fat depots, thigh muscle and fat (computed tomography), fat and lean mass (dual-energy x-ray absorptiometry), intramyocellular and intrahepatic lipids (proton magnetic resonance spectroscopy), mitochondrial function (dynamic phosphorous magnetic resonance spectroscopy), CV risk markers, carotid intimal-medial thickness, and endothelial function. RESULTS: GH administration resulted in a mean IGF-1 SD score increase from -1.9 ± 0.08 to -0.2 ± 0.3 in the GH group and a decrease in visceral adipose tissue (VAT), VAT/sc adipose tissue, trunk/extremity fat, intrahepatic lipids, high-sensitivity C-reactive protein and apolipoprotein B/low-density lipoprotein vs placebo after controlling for the increase in weight observed in both groups. There were inverse associations between change in IGF-1 levels and change in VAT, VAT/sc adipose tissue, trunk fat, trunk/extremity fat, high-sensitivity C-reactive protein, and apolipoprotein B. Mitochondrial function improved in the GH group compared with placebo after controlling for change in glucose. There was no change in thigh fat, muscle mass, intramyocellular lipids, cholesterol, fibrinogen, intimal-medial thickness, or endothelial function. There was no increase in fasting glucose or hemoglobin A1c in the GH vs placebo group, although glucose during the 2-hour oral glucose tolerance test increased slightly. CONCLUSION: GH replacement in abdominally obesemen improves body composition, including liver fat, mitochondrial function, and markers of CV risk. Although fasting glucose was unchanged, a slight increase in 2-hour glucose during an oral glucose tolerance test was noted.
Authors: Hideo Makimura; Meghan N Feldpausch; Alison M Rope; Linda C Hemphill; Martin Torriani; Hang Lee; Steven K Grinspoon Journal: J Clin Endocrinol Metab Date: 2012-09-26 Impact factor: 5.958
Authors: C Rommel; S C Bodine; B A Clarke; R Rossman; L Nunez; T N Stitt; G D Yancopoulos; D J Glass Journal: Nat Cell Biol Date: 2001-11 Impact factor: 28.824
Authors: José Manuel Gómez; Rosa María Espadero; Fernando Escobar-Jiménez; Federico Hawkins; Antonio Picó; José Luis Herrera-Pombo; Enric Vilardell; Alejandra Durán; Jordi Mesa; Eduardo Faure; Anna Sanmartí Journal: Clin Endocrinol (Oxf) Date: 2002-03 Impact factor: 3.478
Authors: Jeremy W Tomlinson; Nicola Crabtree; Penny M S Clark; Geoff Holder; Andrew A Toogood; Cedric H L Shackleton; Paul M Stewart Journal: J Clin Endocrinol Metab Date: 2003-05 Impact factor: 5.958
Authors: Rita Sharma; Quyen Luong; Vishva M Sharma; Mitchell Harberson; Brian Harper; Andrew Colborn; Darlene E Berryman; Niels Jessen; Jens Otto Lunde Jørgensen; John J Kopchick; Vishwajeet Puri; Kevin Y Lee Journal: J Endocrinol Date: 2018-12-01 Impact factor: 4.286
Authors: Miriam A Bredella; Kalypso Karastergiou; Stijn A Bos; Anu V Gerweck; Martin Torriani; Susan K Fried; Karen K Miller Journal: Growth Horm IGF Res Date: 2017-06-12 Impact factor: 2.372
Authors: Miriam A Bredella; Melanie Schorr; Laura E Dichtel; Anu V Gerweck; Brian J Young; Whitney W Woodmansee; Brooke Swearingen; Karen K Miller Journal: J Clin Endocrinol Metab Date: 2017-11-01 Impact factor: 5.958
Authors: Susan K Fried; Karen K Miller; Kalypso Karastergiou; Miriam A Bredella; Mi-Jeong Lee; Steven R Smith Journal: Obesity (Silver Spring) Date: 2016-03-26 Impact factor: 5.002
Authors: Sulaiman R Hamarneh; Caitlin A Murphy; Cynthia W Shih; Walter Frontera; Martin Torriani; Javier E Irazoqui; Hideo Makimura Journal: J Clin Endocrinol Metab Date: 2014-11-06 Impact factor: 5.958
Authors: Laura E Dichtel; Kevin C J Yuen; Miriam A Bredella; Anu V Gerweck; Brian M Russell; Ariana D Riccio; Michelle H Gurel; Patrick M Sluss; Beverly M K Biller; Karen K Miller Journal: J Clin Endocrinol Metab Date: 2014-12 Impact factor: 5.958
Authors: Riley M Bove; Anu V Gerweck; Sarah M Mancuso; Miriam A Bredella; Janet C Sherman; Karen K Miller Journal: Obesity (Silver Spring) Date: 2016-02-16 Impact factor: 5.002